Indeed, compensating for the downregulation of Dcc via CRISPRa targeted gene therapy, and therefore restoring functional DCC receptor protein levels, prevents adult cognitive impairment in males exposed to AMPH in early adolescence. The gene discussed is DCC; the disease is Cognitive impairment.